ADIA · Adia Med, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern for one year after the audit report is dependent upon, among other things, its ability to generate greater revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2025 | FY2024 |
|---|---|---|
| $700.51K | $6380 | |
| $508.84K | $4186 | |
| $191.67K | $2194 | |
| 27.36% | 34.39% | |
| $29.14K | $0 | |
| $479.96K | $140.41K | |
| $4142 | $433 | |
| $558.16K | $176.94K | |
| -$366.49K | -$174.75K | |
| -52.32% | -2739.01% | |
| -$362.35K | -$174.32K | |
| $31.6K | $6318 | |
| -$28.97K | -$6318 | |
| -$395.46K | -$181.07K | |
| $0 | $0 | |
| -$395.46K | -$181.07K | |
| -56.45% | -2838.04% | |
| USD/shares | $0.00 | $0.00 |
| USD/shares | $0.00 | $0.00 |
| shares | 93.6M | 91.74M |
| shares | 93.6M | 91.74M |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of line of credit borrowings | 2026-06-30 | USD 835,312 | 10-Q filed 2026-08-13 |
| Finance lease liabilities | 2026-06-30 | USD 76,455 | 10-Q filed 2026-08-13 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Operating lease liabilities | 2026-06-30 | USD 82,010 | 10-Q filed 2026-08-13 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 15 similar-size Medical Care Facilities companies (of 56 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Adia Labs | $448,888 | $0 |
| AdiaMed | $245,960 | $0 |
| Biolete | $3,393 | $6,380 |
| Corporate | $2,267 | $0 |
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Sales of Prducts and Services | $700,508 | $6,380 |
| Sales of Biologics | $443,750 | $0 |
| Biologics | $289,588 | $0 |
| Medical Procedures | $245,600 | $0 |
| Procedures | $217,955 | $0 |
| Shipping and Delivery | $5,138 | $0 |
| Sales of Supplements | $3,393 | $6,380 |
| Services | $2,267 | $0 |
| Supplements | $1,295 | $4,186 |
| Sales of Ancillary Products | $360 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Adia Labs | $148,783 | -$1,947 |
| Biolete | -$247 | -$25,839 |
| AdiaMed | -$198,889 | -$21,367 |
| Corporate | -$316,139 | -$125,596 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 |
|---|---|---|
| Adia Labs | 33.1% | — |
| AdiaMed | -80.9% | — |
| Biolete | -7.3% | -405% |
| Corporate | -13945.3% | — |